Suppr超能文献

肿瘤内龛位维持并分化具有干细胞样特征的 CD8+T 细胞。

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

机构信息

Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.

Winship Cancer Institute of Emory University, Atlanta, GA, USA.

出版信息

Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.

Abstract

Tumour-infiltrating lymphocytes are associated with a survival benefit in several tumour types and with the response to immunotherapy. However, the reason some tumours have high CD8 T cell infiltration while others do not remains unclear. Here we investigate the requirements for maintaining a CD8 T cell response against human cancer. We find that CD8 T cells within tumours consist of distinct populations of terminally differentiated and stem-like cells. On proliferation, stem-like CD8 T cells give rise to more terminally differentiated, effector-molecule-expressing daughter cells. For many T cells to infiltrate the tumour, it is critical that this effector differentiation process occur. In addition, we show that these stem-like T cells reside in dense antigen-presenting-cell niches within the tumour, and that tumours that fail to form these structures are not extensively infiltrated by T cells. Patients with progressive disease lack these immune niches, suggesting that niche breakdown may be a key mechanism of immune escape.

摘要

肿瘤浸润淋巴细胞与多种肿瘤类型的生存获益以及对免疫治疗的反应有关。然而,为什么有些肿瘤有高的 CD8 T 细胞浸润,而有些则没有,原因尚不清楚。在这里,我们研究了维持针对人类癌症的 CD8 T 细胞反应的要求。我们发现,肿瘤内的 CD8 T 细胞由终末分化和干细胞样细胞的不同群体组成。在增殖过程中,干细胞样 CD8 T 细胞产生更多的终末分化、效应分子表达的子细胞。为了使许多 T 细胞浸润肿瘤,关键是要发生这种效应分化过程。此外,我们还表明,这些干细胞样 T 细胞存在于肿瘤内密集的抗原呈递细胞巢中,而不能形成这些结构的肿瘤则不能被 T 细胞广泛浸润。进展性疾病患者缺乏这些免疫巢,提示巢破坏可能是免疫逃逸的关键机制。

相似文献

1
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.
2
PGE limits effector expansion of tumour-infiltrating stem-like CD8 T cells.
Nature. 2024 May;629(8011):417-425. doi: 10.1038/s41586-024-07254-x. Epub 2024 Apr 24.
3
Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer.
Nature. 2021 Sep;597(7875):279-284. doi: 10.1038/s41586-021-03862-z. Epub 2021 Sep 1.
4
TOX is a critical regulator of tumour-specific T cell differentiation.
Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.
5
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24.
6
Organized immune cell interactions within tumors sustain a productive T-cell response.
Int Immunol. 2021 Jan 1;33(1):27-37. doi: 10.1093/intimm/dxaa057.
7
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Nature. 2024 Dec;636(8041):224-232. doi: 10.1038/s41586-024-08076-7. Epub 2024 Oct 23.
8
NR4A transcription factors limit CAR T cell function in solid tumours.
Nature. 2019 Mar;567(7749):530-534. doi: 10.1038/s41586-019-0985-x. Epub 2019 Feb 27.
9
Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates.
Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. Epub 2018 May 16.

引用本文的文献

2
A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.
Cancer Immunol Immunother. 2025 Aug 7;74(9):286. doi: 10.1007/s00262-025-04102-3.
3
Lymph-node-derived stem-like but not tumor-tissue-resident CD8 T cells fuel anticancer immunity.
Nat Immunol. 2025 Aug;26(8):1367-1383. doi: 10.1038/s41590-025-02219-2. Epub 2025 Jul 29.
5
CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA.
J Mol Med (Berl). 2025 Jul 17. doi: 10.1007/s00109-025-02574-5.
6
Multimodal delineation of a layer of effector function among exhausted CD8 T cells in tumors.
Sci Immunol. 2025 Jul 11;10(109):eadt3537. doi: 10.1126/sciimmunol.adt3537.
10
Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable model of exhaustion.
Immunother Adv. 2025 Jun 11;5(1):ltaf023. doi: 10.1093/immadv/ltaf023. eCollection 2025.

本文引用的文献

1
Tertiary lymphoid structures in the era of cancer immunotherapy.
Nat Rev Cancer. 2019 Jun;19(6):307-325. doi: 10.1038/s41568-019-0144-6.
2
Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade.
Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18.
4
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1CD8 Tumor-Infiltrating T Cells.
Immunity. 2019 Jan 15;50(1):181-194.e6. doi: 10.1016/j.immuni.2018.11.014. Epub 2019 Jan 8.
5
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038.
6
High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors.
J Exp Med. 2018 Oct 1;215(10):2520-2535. doi: 10.1084/jem.20180684. Epub 2018 Aug 28.
7
Human Lymph Nodes Maintain TCF-1 Memory T Cells with High Functional Potential and Clonal Diversity throughout Life.
J Immunol. 2018 Oct 1;201(7):2132-2140. doi: 10.4049/jimmunol.1800716. Epub 2018 Aug 15.
8
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Nat Med. 2018 Jul;24(7):986-993. doi: 10.1038/s41591-018-0078-7. Epub 2018 Jun 25.
9
Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates.
Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. Epub 2018 May 16.
10
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050. doi: 10.1073/pnas.1720948115. Epub 2018 Apr 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验